Email Alert | RSS

Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (7): 729-734.doi: 10.3969/j.issn.1000-6621.2021.07.015

Previous Articles     Next Articles

Research and development/exploitation of therapeutic drugs for NTM pulmonary disease:present situation and challenges

ZHENG Lu-yao*, LU Yu(), CHEN Xiao-you()   

  1. *Beijing Key Laboratory of Drug Resistance Tuberculosis Research,Department of Pharmacology,Beijing Tuberculosis and Thoracic Tumor Research Institute,Beijing Chest Hospital,Capital Medical University,Beijing 101149,China
  • Received:2021-04-02 Online:2021-07-10 Published:2021-07-09
  • Contact: ZHENG Lu-yao,LU Yu,CHEN Xiao-you E-mail:luyu4876@hotmail.com;chenxy1998@hotmail.com

Abstract:

Non-tuberculous mycobacteria (NTM) belongs to the genus mycobacterium,which is “close relative” to Mycobacterium tuberculosis. In recent years, the prevalence of chronic lung diseases caused by NTM is increasing at an alarming rate, even exceeding Mycobacterium tuberculosis in some countries. At present, the clinical treatment mainly relies on long-term therapy with combined medication, but the results are often unsatisfactory. Therefore, there is an urgent need for noval and more effective antimicrobials as well as new chemotherapy regimen. This article reviews the current situation and challenges in NTM drug development, in order to provide new insight for the treatment of NTM pulmonary disease.

Key words: Mycobacterium infections, atypical, Antitubercular agents, Review literature as topic